Abstract: The invention generally relates to compositions and methods for preventing sternal wound infections, such as mediastinitis. In certain embodiments, the invention provides an antimicrobial composition including at least one bioresorbable polymer, such as a tyrosine-derived polyesteramide, and at least one antimicrobial agent, in which the composition is adapted to be topically applied to an esophageal perforation in a subject or a median sternotomy incision site in the subject, and in which the at least one antimicrobial agent is present in an amount effective to inhibit development of mediastinitis in the subject.
Type:
Grant
Filed:
June 1, 2010
Date of Patent:
December 12, 2017
Assignee:
TYRX, Inc.
Inventors:
Raman Bahulekar, Arikha Moses, Satish Pulapura, William C. McJames, II, Fatima Buevich
Abstract: The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
Type:
Grant
Filed:
January 7, 2016
Date of Patent:
December 12, 2017
Assignee:
Zafgen, Inc.
Inventors:
David Clark, Susan M. Cramp, Hazel J. Dyke, Thomas D. Pallin, Robert Zahler
Abstract: The present invention provides the use of certain compounds to treat peripheral or central pain syndrome and other disorders associated with the T-type calcium ion channels.
Abstract: Compositions with fulvate fractions alone or in combination with growth factors, bioactive fragmented peptides, or combinations thereof are disclosed herein. Also disclosed are methods of using said compositions for the catalyzing cellular regeneration, including the healing, treatment, or prevention of skin disorders. Also disclosed are methods for extracting, isolating, and purifying fulvate fractions for use in the manufacture of said compositions.
Type:
Grant
Filed:
November 23, 2016
Date of Patent:
November 21, 2017
Assignee:
Omni Bioceutical Innovations, Inc.
Inventors:
Gary W. Black, Jane Christensen, Farhan Taghizadeh
Abstract: The present invention relates to a phosphopeptide-stabilized amorphous calcium phosphate and/or amorphous calcium fluoride phosphate complex, wherein the complex is formed at a pH of below 7.0. Methods of making such complexes are also provided. The complexes are useful in dental applications, in particular in dental remineralization.
Abstract: Provided herein are compounds, compositions, pharmaceutical formulations, methods of treating and methods of using aPKC inhibitors for treating and/or preventing of aPKC abnormalities.
Type:
Grant
Filed:
July 30, 2014
Date of Patent:
October 24, 2017
Assignee:
University of South Florida
Inventors:
Robert Vito Farese, Mini Paliyath Sajan
Abstract: The inventive subject matter relates to the use of L-butylphthalide in the manufacturing of medicaments for the prevention and treatment of cerebral ischemia-induced disease. Cerebral ischemia of the animals or human induces cerebral infarction, neurological deficit, memory disorder, cerebral edema, cerebral apoplexy, metabolic disorder of energy, changes of cerebral blood flow, and the like. The in vivo experiments show that L-butylphthalide can effectively reduce the above-mentioned adverse symptoms induced by cerebral ischemia.
Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-?) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-?) inhibitors, and to methods for regulating angiogenesis.
Type:
Grant
Filed:
February 5, 2016
Date of Patent:
October 24, 2017
Assignee:
AERPIO THERAPEUTICS, INC.
Inventors:
Jeffrey Lyle Gray, Kande K. D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier
Abstract: The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.
Type:
Grant
Filed:
May 14, 2014
Date of Patent:
October 10, 2017
Assignee:
The Board of Regents of the University of Texas System
Abstract: The present invention provides a pharmaceutical composition for removing drusen, suppressing formation of drusen, and/or treating and/or preventing age-related macular degeneration comprising the compound of formula (I) wherein Ra is independently selected from the group consisting of halo, hydroxy, alkyl, halo-substituted alkyl, aryl, halo- or alkyl-substituted aryl, alkoxy, hydroxy- or carboxy-substituted alkoxy, aryloxy, halo- or alkyl-substituted aryloxy, CHO, C(O)-alkyl, C(O)-aryl, C(O)-alkyl-carboxyl, C(O)-alkylene-carboxy ester and cyano, and m is an integer selected from 0 to 4.
Abstract: A family of covalent kinetic stabilizer compounds that selectively and covalently react with the prominent plasma protein transthyretin in preference to more than 4000 other human plasma proteins is disclosed. A contemplated compound corresponds in structure to Formula I, below, where the various substituents are defined within, and reacts chemoselectively with one or two of four Lys-15 ?-amino groups within the transthyretin tetramer. The crystal structure confirms the binding orientation of the compound substructure and the conjugating amide bond. A covalent transthyretin kinetic stabilizer exhibits superior amyloid inhibition potency, compared to a non-covalent counterpart, and inhibits cytotoxicity associated with amyloidogenesis.
Abstract: The present disclosure relates to novel platinum compositions having a heterocycle ligand and nanoparticles and methods using such compositions, e.g. for treating cancer.
Type:
Grant
Filed:
July 16, 2014
Date of Patent:
September 26, 2017
Assignee:
PLACON THERAPEUTICS
Inventors:
Adam H. Brockman, Mark T. Bilodeau, BenoƮt Moreau, Edward R. Lee
Abstract: Various organic molecules, ingredients and compositions are prepared from Stevia rebaudiana plant. The compositions can be used as bulking agents, and sweeteners in foods, beverages, cosmetics and pharmaceuticals.
Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
Type:
Grant
Filed:
April 22, 2016
Date of Patent:
September 19, 2017
Assignee:
PURDUE PHARMA L.P.
Inventors:
Alexander Oksche, William Heath, Timothy Holden, Derek A. Prater, Richard S. Sackler, Malcolm Walden
Abstract: The present invention relates to organo-arsenoxide compounds and to methods for their synthesis. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in the treatment of diseases and disorders, in particular proliferative diseases and disorders, including treatment of solid tumors and leukaemia.
Abstract: The present invention provides 4-substituted-3-{phenyl[(heterocyclylmethoxy)imino]methyl}-1,2,4-oxadiazol-5(4H)-one derivatives of formula (I) Wherein A and X1 to X3 and Y1 to Y5 represent various substituents.
Type:
Grant
Filed:
March 3, 2014
Date of Patent:
August 29, 2017
Assignee:
BAYER CROPSCIENCE AKTIENGESELLSCHAFT
Inventors:
Anne-Sophie Rebstock, Christophe Dubost, Pierre-Yves Coqueron, Simon Maechling, Helene Lachaise, Philippe Rinolfi, Ulrike Wachendorff-Neumann, Christoph Andreas Braun
Abstract: The present invention encompasses compounds of the formula (I): wherein the variables are defined herein which are suitable for the modulation of RORC and the treatment of diseases related to the modulation of RORC. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
Type:
Grant
Filed:
September 4, 2014
Date of Patent:
August 29, 2017
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Brian Nicholas Cook, John D. Huber, Robert Owen Hughes, Thomas Martin Kirrane, Jr., Celina Lasota, Xiang Li, Shuang Liang, Ingo Andreas Mugge, Qiang Zhang